← Back
Research Paper Volume 12, Issue 14 pp 14406—14417

Osthole resensitizes CD133+ hepatocellular carcinoma cells to cisplatin treatment via PTEN/AKT pathway

class="figure-viewer-img"

Figure 3. Osthole partially reversed the cisplatin resistance of CD133+ HCC cells. (A) Combination treatment with osthole (10 μmol/L) increased the cytotoxicity of cisplatin (0~30 μM) against CD133+ Huh7 and HepG2 cells. *P<0.05. (B) Osthole (10 μmol/L) decreased the IC50 of cisplatin to CD133+ Huh7 and HepG2 cells. #P<0.05 vs. Control group. (C) Effect of osthole (10 μmol/L) on decreasing the IC50 of cisplatin to CD133- Huh7 and HepG2 cells. #P<0.05 vs. Control group.